Zusammenfassung
Die Sklerodermie stellt eine relativ seltene Erkrankung des rheumatischen Formenkreises dar. Jährlich erkranken 4 - 20 Menschen unter 1 Million Einwohnern bundesweit an der Systemischen Form, 27 Menschen unter 1 Million Einwohnern an der zirkumskripten Sklerodermie (CSS). Mit der internen Gabe von Immunmodulatoren bei der PSS und Bestrahlungen mit dem langwelligen UVA1-Licht bei der zirkumskripten Sklerodermie (CSS), sowie physiotherapeutischen Maßnahmen, topischen Anwendungen mit Vitamin D-Derivaten und naturheilkundlichen Produkten wie Dulcamaris, steht der Medizin ein großes Repertoire an therapeutischen Interventionsmöglichkeiten zur Verfügung. In diesem Artikel besprechen wir aktuelle Empfehlungen in der Diagnostik und Therapie der Sklerodermie im Kindes- und Erwachsenenalter. Besonders gehen wir auf die Rolle der UVA1-Bestrahlung in der Therapie ein. Darüber hinaus werden Einsatzmöglichkeiten der biomechanischen Stimulation (BMS), Lymphdrainagen und Massagen diskutiert.
Abstract
Scleroderma represents a relatively rare rheumatic disease, 4 - 20 new cases of progressive systemic scleroderma (PSS) and 27 new cases of morphea under 1 million inhabitants are known. With systemic immunomodulation in PSS and UVA1 therapy in case of morphea, as well as physiotherapy, there is a large repertoire of therapeutic tools. In this article we discuss current recommendations in diagnostics and therapy of scleroderma in childhood and adult age, particularly the role of UVA1 therapy. Additionally the application of biomechanical stimulation (BMS), manual lymph drainage and massage are discussed.
Literatur
-
1
Arbeitsgruppe Sklerodermie der Arbeitsgemeinschaft Dermatologische Forschung (ADF) .
Zur Klassifikation der zirkumskripten Sklerodermie (CS).
Hautarzt.
1990;
41
16-21
-
2
Baxter A M, Roberts A, Shaw L, Chapple I L.
Localized scleroderma in a 12-year-old girl presenting as gingival recession. A case report and literature review.
Dent Update.
2001;
28
458-462
-
3
Bodemer C, Amoric J C, Hamel-Teillac D, De Prost Y.
Localized scleroderma in children and a therapeutic trial using calcitriol: a therapeutic possibility to define.
Ann Dermatol Venereol.
1999;
126
725-726
-
4
Bodemer C, Belon M, Hamel-Teillac D, Amoric J C, Fraitag S, Prieur A M, De Prost Y.
Scleroderma in children: a retrospective study of 70 cases.
Ann Dermatol Venereol.
1999;
126
691-694
-
5
Cunningham B B, Landells I D, Langman C, Sailer D E, Paller A S.
Topical calcipotriene for morphea/linear scleroderma.
J Am Acad Dermatol.
1998;
39
211-215
-
6
De Keyser F, Peene I, Joos R, Naeyaert J M, Messiaen L, Veys E M.
Occurrence of scleroderma in monozygotic twins.
J Rheumatol.
2000;
27
2267-2269
-
7
El-Mofty M, Zaher H, Bosseilia M, Yousef R, Saad B.
Low-dose broad-band UVA in morphea using a new method for evaluation.
Photodermatol Photoimmunol Photomed.
2000;
16
43-49
-
8
Elst E F, Van Suijlekom-Smit L W, Oranje A P.
Treatment of linear scleroderma with oral 1,25-dihydrosyvitamin D3 (calcitriol) in seven children.
Pediatr Dermatol.
1999;
16
53-58
-
9
Emery H.
Pediatric scleroderma.
Semin Cutan Med Surg.
1998;
17
41-47
-
10
Hawk A, English J C 3rd.
Localizid and systemic scleroderma.
Semin Cutan Med Surg.
2001;
20
27-37
-
11
Kerscher M, Dirschka T, Volkenandt M.
Treatment of localised scleroderma by UVA1 phototherapy.
Lancet.
1995;
28
1166
-
12
Kerscher M, Volkenandt M, Gruss C, Reuther T, von Kobyletzki G, Freitag M, Dirschka T, Altmeyer P.
Low-dose UVA phototherapy for treatment of localized scleroderma.
J Am Acad Dermatol.
1998;
38
21-26
-
13
Krafchik B R.
Localized morphea in children.
Adv Exp Med Biol.
1999;
455
49-54
-
14
Kreuter A, Gambichler T, Avermaete A, Happe M, Bacharach-Buhles M, Hoffmann K, Jansen T, Altmeyer P, von Kobyletzki G.
Low-dose ultraviolett A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study.
J Am Acad Dermatol.
2002;
46
251-255
-
15
Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J.
UVA1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis.
J Am Acad Dermatol.
2000;
43
670-674
-
16
Papadimitriou A, Chroni E, Anastasopoulos I, Avramidis T, Hadjigeorgiou G, Koutroumanidis M.
Continous muscle fiber activity associated with morphea (localized scleroderma).
Neurology.
1998;
51
1763-1764
-
17
Pastor Oliver J F, CalcedoAscoz A, Paricio Talayero J M, Santos Serrano L, Fernandez Feijoo A, Ferriol Camacho M.
Localized scleroderma: lesion „en coup de sabre”. Review of the literature and report of a case.
An Esp Pediatr.
1998;
49
499-502
-
18
Rai R, Handa S, Gupta S, Kumar B.
Bilateral en coup de sabre - a rare entity.
Pediatr Dermatol.
2000;
17
222-224
-
19
Scharffetter K, Kind P, Wollny-Protzel D, Schuppe H C, Lakomek H J, Goerz G.
Die Sklerodermien.
Z Hautkr.
1990;
65
237-246
-
20
Tuffanelli D L.
Localized scleroderma.
Semin Cutan Med Surg.
1998;
17
27-33
-
21
Uziel Y, Feldman B M, Krafchik B R, Yeung R S, Laxer R M.
Methotrexate and corticosteroid therapy for pediatric localized scleroderma.
J Pediatr.
2000;
136
91-95
-
22
Vierra E, Cunningham B B.
Morphea a localized scleroderma in children.
Semin Cutan Med Surg.
1999;
18
210-225
-
23
Weinberg J M, Russo M, Hirsch R J, Don P C.
Morphoea of the breast in a young girl.
Clin Exp Dermatol.
2001;
26
497-498
-
24
Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N, Tamakai K.
Anti-U1RNP antibodies in patients with localized scleroderma.
Arch Dermatol Res.
2001;
293
455-459
Prof. Dr. med. Martina Bacharach-Buhles
Bredenscheider Str. 54 · 45525 Hattingen
